Revolune Launches Spatial Biology Company
Analysis based on 6 articles · First reported Apr 15, 2026 · Last updated Apr 15, 2026
The launch of Revolut introduces a new player in the life science and biotechnology markets, potentially increasing competition and offering new solutions for spatial biology. This could positively impact research and development in biopharma, leading to advancements that benefit the broader market.
Revolut, a new life science company, officially launched on April 15, 2026, with a mission to advance spatial biology through streamlined multiplex immunofluorescence (mIF) reagents. The company aims to simplify complex tissue analysis workflows for translational and biopharma research, addressing existing challenges in reproducibility and operational friction. Florian Leiss, CEO of Revolut, previously led strategic initiatives within the Zeiss (company) ecosystem, which led to Revolut's creation as an independent spin-out. Michaeli Deli joins as CFO. Revolut is also initiating an Early Access Program to collaborate with research groups on its new technologies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard